Your browser is no longer supported. Please, upgrade your browser.
Aileron Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own5.79% Shs Outstand90.30M Perf Week-10.92%
Market Cap89.25M Forward P/E- EPS next Y-0.39 Insider Trans184.48% Shs Float74.44M Perf Month-10.92%
Income-21.20M PEG- EPS next Q-0.05 Inst Own29.70% Short Float2.01% Perf Quarter-47.26%
Sales- P/S- EPS this Y49.30% Inst Trans136.58% Short Ratio1.02 Perf Half Y-5.36%
Book/sh0.30 P/B3.53 EPS next Y-34.50% ROA-99.50% Target Price- Perf Year51.43%
Cash/sh0.16 P/C6.47 EPS next 5Y2.10% ROE-165.80% 52W Range0.64 - 2.47 Perf YTD1.92%
Dividend- P/FCF- EPS past 5Y7.20% ROI- 52W High-57.09% Beta2.74
Dividend %- Quick Ratio4.10 Sales past 5Y- Gross Margin- 52W Low65.62% ATR0.10
Employees8 Current Ratio4.10 Sales Q/Q- Oper. Margin- RSI (14)37.30 Volatility9.40% 8.54%
OptionableNo Debt/Eq0.03 EPS Q/Q53.10% Profit Margin- Rel Volume0.47 Prev Close1.06
ShortableYes LT Debt/Eq0.02 EarningsMay 11 AMC Payout- Avg Volume1.47M Price1.06
Recom1.70 SMA20-9.59% SMA50-21.18% SMA200-23.45% Volume688,717 Change0.00%
Jul-24-17Initiated William Blair Outperform
Jul-24-17Initiated Jefferies Buy $20
Jul-24-17Initiated BofA/Merrill Buy $19
May-11-21 04:18PM  
Mar-24-21 04:36PM  
Mar-04-21 08:30AM  
Mar-02-21 07:00AM  
Jan-11-21 06:30AM  
Jan-06-21 09:30AM  
Dec-23-20 03:41AM  
Dec-21-20 08:00AM  
Dec-14-20 08:32AM  
Dec-01-20 10:12AM  
Nov-29-20 08:33PM  
Nov-24-20 08:28AM  
Nov-19-20 10:02AM  
Nov-12-20 07:03PM  
Oct-24-20 04:35AM  
Oct-20-20 09:24AM  
Oct-13-20 08:30AM  
Oct-12-20 07:00AM  
Sep-21-20 06:07PM  
Sep-10-20 08:45AM  
Aug-25-20 01:25PM  
Aug-05-20 04:10PM  
Aug-04-20 03:31PM  
Aug-03-20 08:10AM  
Jun-29-20 08:30AM  
Jun-12-20 11:42AM  
Jun-10-20 09:54AM  
Jun-04-20 09:15AM  
Jun-03-20 04:01PM  
Jun-02-20 10:22AM  
Jun-01-20 08:34AM  
May-27-20 08:30AM  
May-11-20 08:30AM  
Apr-22-20 08:30AM  
Mar-30-20 04:16PM  
Dec-20-19 05:45PM  
Dec-19-19 06:07AM  
Dec-18-19 08:30AM  
Nov-07-19 07:30AM  
Oct-31-19 08:30AM  
Oct-29-19 08:00AM  
Oct-21-19 08:00AM  
Oct-16-19 08:30AM  
Sep-28-19 07:30AM  
Sep-24-19 05:00PM  
Sep-19-19 07:24AM  
Sep-09-19 08:00AM  
Sep-03-19 05:10PM  
Aug-06-19 04:10PM  
Jul-30-19 07:03PM  
Jul-17-19 02:38PM  
Jun-27-19 08:00AM  
Jun-24-19 08:00AM  
May-30-19 08:00AM  
May-08-19 04:57PM  
May-01-19 06:31PM  
Apr-03-19 12:15PM  
Mar-29-19 09:00AM  
Mar-04-19 09:00AM  
Feb-01-19 02:31PM  
Jan-29-19 09:25AM  
Jan-16-19 12:47PM  
Dec-21-18 11:33AM  
Dec-04-18 09:13AM  
Nov-28-18 10:22AM  
Nov-27-18 08:00AM  
Nov-19-18 08:25AM  
Nov-07-18 04:10PM  
Nov-05-18 04:05PM  
Nov-01-18 04:05PM  
Oct-30-18 04:05PM  
Oct-19-18 08:00AM  
Sep-06-18 09:00AM  
Aug-07-18 04:15PM  
Aug-02-18 07:00AM  
Jul-31-18 07:00AM  
May-29-18 07:00AM  
May-22-18 05:00AM  
May-15-18 04:05PM  
May-09-18 04:03PM  
Apr-11-18 04:05PM  
Apr-02-18 04:09PM  
Mar-28-18 07:00AM  
Mar-19-18 07:00AM  
Dec-11-17 04:30PM  
Nov-09-17 04:18PM  
Nov-01-17 09:19AM  
Oct-05-17 06:40AM  
Sep-19-17 07:00AM  
Aug-24-17 07:00AM  
Aug-10-17 04:11PM  
Aug-03-17 07:00AM  
Jul-19-17 09:21AM  
Jul-07-17 12:46PM  
Jul-03-17 01:02PM  
Jun-28-17 10:06PM  
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Satter Muneer ASee RemarksJan 08Buy1.109,000,0009,900,00016,609,449Jan 08 04:15 PM
Ambros Reinhard J.DirectorJun 15Buy1.225,8007,0765,800Jun 17 04:31 PM
Satter Muneer ADirectorJun 08Buy1.103,700,0004,070,0007,609,449Jun 09 08:22 PM
VON RICKENBACH JOSEF HDirectorJun 08Buy1.10227,272249,999445,460Jun 09 08:23 PM